HHLA2(B7H7) aAPC Cell-南京科佰生物科技有限公司

产品搜索

联系人：蒋经理
电话：4008750250
号码：
手机：18066071954
地址：南京市栖霞区纬地路9号
Email： zhangxiangwen@cobioer.com

CBP74194
I. Background
HHLA2 (a B7 family member) has both immune inhibitory and activating abilities and is expressed in many human cancers. These differing functions rely on the receptor to which it binds, yet many of these receptors are uncharacterized. Here, Wei et al. found that KIR3DL3 bound to HHLA2 and was expressed on effector memory CD8⁺ T cells and CD56^dim NK cells. Interactions of KIR3DL3 with tumoral HHLA2 inhibited the function and killing capacity of both CD8⁺ T cells and NK cells. KIR3DL3⁺ immune cells infiltrated various types of HHLA2⁺ tumors from patients with cancer, and blockade of KIR3DL3 inhibited the growth of tumors in various mouse models. Thus, KIR3DL3-HHLA2 inhibits immune-mediated clearance of tumor cells and presents a possible immunotherapeutic target for cancer.

II. Introduction
Expressed gene:	HHLA2(B7H7)
Stability:	32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Freeze Medium:	90% FBS+10% DMSO
Culture Medium:	F12K+10%FBS+2ug/ml puromycin+500ug/ml hygromycin
Mycoplasma Testing:	Negative
Storage:	Liquid nitrogen
Application(s):	Functional(Report Gene) Assay

III. Representative Data
Figure 1. Dose Response of HHLA2 Blocking Abs in KIR3DL3 Effector Reporter Cells (C1)With HHLA2(B7H7) aAPC Cells.